Craving value: How fast-food brands can win in APAC's diverse market
Want to conquer APAC's diverse fast-food scene? Discover the nuances you need to master to win over consumers.
Launched with great promise in a climate of escalating drug costs, biosimilars have generated as many questions as answers for more than a decade.
Why does biosimilar adoption vary, even with significant discounts? What factors beyond price are encouraging or deterring biosimilar usage? And how do these factors affect the ultimate choice of a biologic vs biosimilar?
Published on the Pharmaceutical Market Europe (PME) December 2017 issue, our senior research manager, Adriënne discussed what prescribers are thinking when deciding between biologic vs biosimilar.
“To answer these questions, we surveyed physician key opinion leaders (KOLs) working in oncology and haematology across leading EU markets.
Survey discussions were designed to explore their perceptions and intentions regarding future use of MAb biosimilars. The results revealed consistent attitudes regarding several key issues that affect prescribing behavior. They include:
Be the first to receive the latest market research insights, tips from industry peers and exclusive content to help you influence decision behavior.
Want to conquer APAC's diverse fast-food scene? Discover the nuances you need to master to win over consumers.
Drowning in data? Learn how to turn information overload into a competitive advantage with these actionable principles.
Explore insights into consumer perceptions of price and promotions to optimize revenue management strategies and drive sustainable growth.
SKIM has named Maura Coracini as Managing Director, Latin America. Based in the São Paulo area.